Strategic Acquisition CTL recently became part of a larger corporate narrative through acquisition by VION Biosciences, suggesting expanded distribution, integration opportunities, and cross-sell of CTL’s ELISPOT platforms, kits, and services into VION’s diagnostics and drug development workflows.

Expanded ImmunoMonitoring With a CLIA-certified, GLP-compliant lab capable of processing up to 450 samples weekly and a comprehensive ELISPOT ecosystem, CTL presents a ready-to-sell solution for contract research organizations, pharma, and academic labs seeking scalable immune monitoring services.

Comprehensive Library CTL offers the largest commercially available cryopreserved PBMC library with established T cell reactivity, enabling near-term opportunities to license or partner for reference standards, assay validation, and benchmarking across ELISPOT and FluoroSpot workflows.

End-to-End Solutions The portfolio spans reagents, kits, analyzers, and data processing services, presenting cross-sell potential to labs needing integrated Immune Monitoring, data analysis, and audit-trail compliant reporting within a single provider.

Tech & Training CTl’s ImmunoSpot and BioSpot analyzers, multicolor FluoroSpot kits, and hands-on workshops position CTL as both a supplier and solutions partner for upskilling customer teams, enabling education-led upsell and recurring training service opportunities.